Size 8 women are calling themselves fat in a 'disturbing hierarchy' of slimness
The realisation hit me like a slap in the face, but it's not that I think I'm overweight, I know I'm perfectly healthy.
It's because a girl who had exactly my body type posted a 'before and after' TikTok of her going from slim to toned, and my body was her 'before'.
She still looked great in the 'before', and by great I mean totally and completely normal. Her tummy just folded over her jeans a little as she slouched, as mine does, too. The after shot shows her with very little visble body fat.
I headed to the comments expecting to see people telling her she already looked amazing and didn't need to lose that weight, but that wasn't what greeted me.
A girl had written: 'I need this bc I'm like skinny fat.' And it had close to 11,000 likes.
Society has decided being slim is no longer good enough, now we have to be lean and toned like an athlete or model. I'd always had the luxury of being born with a body that social media deems 'acceptable' – until now.
The widespread use of Ozempic and other weight loss jabs has 'reset the visual benchmark' for what is considered 'skinny', says Dr Suzanne Wylie, GP and medical adviser for IQdoctor.
'It has created a disturbing hierarchy, where even naturally slim individuals feel they must go to further extremes to maintain their status or avoid criticism,' she tells Metro.
'Skinny fat' isn't a new term – historically, it's been used to describe a body type where individuals have a higher portion of visceral fat around their organs, depsite a 'healthy' BMI range. But let's be clear: this latest iteration of the phrase is about aesthetics, not health.
Whereas five or six years ago the body positivity movement made it taboo to post this kind of content, it feels somehow socially acceptable again.
And though TikTok has banned various hashtags associated with 'skinnytok', the algorithm has served me video after video of how to get rid of my 'skinny fat'.
I know it's toxic and unnecessary, so why do I feel the need to do so?
'I'm increasingly concerned about the impact of social media trends on young people's perceptions of health and body image,' Dr Suzanne tells me.
'The idea that someone who is a size six or eight and not visibly toned might consider themselves fat, speaks to a deepening misunderstanding of body composition, health, and self-worth.'
She adds that terms like 'skinny fat' reflect a shift in what we deem healthy or desirable, and having zero fat on your body isn't good for you.
'Having some body fat is not only normal, it is essential,' Dr Suzanne explains. 'Fat plays a critical role in hormone production and immune function.
'Maintaining a healthy level of body fat is vital for menstrual function and fertility. So striving for an extremely low body fat percentage, in pursuit of muscle definition, can actually be detrimental to long-term health.'
The bottom line is that being toned doesn't necessarily equate to being healthy, especially if you're going to try and achieve it by restricting food or exercising excessively.
'I regularly see young women with perfectly healthy BMIs and good cardiovascular fitness who nonetheless feel inadequate because they don't match an airbrushed or filtered online ideal,' Dr Suzanne says.
'The pressure to be lean, rather than just slim, is intensifying.'
Serena Novelli, body confidence coach and founder of Love Thy Body, agrees, saying: 'This trend masks that tone has as much to do with muscle as it does with shape, and muscle needs strength, not shame, to grow.'
Disturbingly, Dr Suzanne says she's seen an uptick in young women who come to her deeply unhappy with their appearance, despite being fit and healthy.
'It's worrying, because this can quickly spiral into more serious conditions such as anorexia nervosa or bulimia – especially when combined with perfectionist personality traits or low self-esteem.' @marie_xoxo_
Its a vibe 😌 #fyp ♬ original sound – songs n lyrics
Serena wants to reiterate that 'bodies are not trends, they're homes' – a mantra more important than ever in an era increasingly defined by filters, AI and weight loss jabs. More Trending
'That little fold of skin when we bend? It's human. It's normal,' she says.
'Women have been conditioned to critique themselves endlessly, but we need less comparison and more compassion.
View More »
'Instead of chasing another standard, let's come home to our bodies, soft, strong, ever-changing and worthy as they are.'
Do you have a story to share?
Get in touch by emailing MetroLifestyleTeam@Metro.co.uk.
MORE: Feminist hero Gisele Pelicot receives France's highest civilian honour
MORE: I'm a millennial – please stop sending me perimenopause memes
MORE: Until I had one, I was ignorant about the reality of miscarriages
Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Herald Scotland
an hour ago
- The Herald Scotland
Weight loss jab Mounjaro linked to lower dementia risk
People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025 Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: — NHS Dorset (@NHSDorset) June 23, 2025 During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Scottish Sun
an hour ago
- Scottish Sun
The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers'
Plus, the truth about fat jabs - where to get them, how they work, and the hidden risks you need to know WEIGH TO GO The brain busting side-effects of Ozempic-like fat jabs revealed – 'slashing risk of silent killers' THEY'VE been hailed as miracle weight-loss jabs - but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called 'skinny pens' may also supercharge your brain and protect against two killer diseases. 3 Fat jabs could keep your brain healthy, experts says Credit: Getty 3 The popular medicines could reduce the risk of demenita and stroke Credit: Getty Scientists from Taiwan found that these fat-busting jabs may help lower the chances of developing dementia and stroke. People with type 2 diabetes and obesity who took the drugs were also less likely to die early, the researchers discovered. While everyone knows these drugs, like Wegovy and Mounjaro, help with weight and blood sugar control, experts say some of their other benefits are still a bit of a mystery. For the study, published in JAMA Network Open, experts from Chang Gung Memorial Hospital looked at data from 60,000 people around the world. The average age was 58 and all had type 2 diabetes and obesity. About half of the group were given drugs called GLP1-RAs. These include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to manage their diabetes. Semaglutide is also the main ingredient in the popular diabetes drug Ozempic, which is licensed for diabetes, while Wegovy is licensed for weight loss. These drugs work by lowering appetite, slowing digestion, reducing sugar production in the liver, and helping the body make more insulin when needed. The other half of the participants were on different diabetes medications. After following everyone for seven years, the researchers found the people using GLP1-RAs had a 37 percent lower risk of dementia and were 19 percent less likely to have a stroke. Weight Loss Jabs - Pros vs Cons These conditions are often called silent killers because they can creep up without obvious symptoms until it's too late. The experts also found those on the drugs were 30 per cent less likely to die during the study period. The team saw even bigger benefits in people over 60, women, and those with a body mass index between 30 and 40. There was no difference in the chances of Parkinson's disease or brain bleeds between the groups. The academics said their findings suggest "potential neuroprotective and cerebrovascular benefits" of the drugs but they called for more studies to confirm the research. 3 Wegovy and Mounjaro are already hailed as wonder drugs for blood sugar control and dramatic weight los Credit: Alamy "These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity," they wrote. Commenting on the study, Professor Tara Spires-Jones, from the University of Edinburgh, said: "This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. "This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. "It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. "Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity." 'This is a really exciting ' Dr Richard Oakley, from the Alzheimer's Society, said: "It is well established that diabetes and obesity can increase your risk of developing dementia. "This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. "Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. "There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia."
The Sun
an hour ago
- The Sun
The brain busting side-effects of Ozempic-like fat jabs revealed – ‘slashing risk of silent killers'
THEY'VE been hailed as miracle weight-loss jabs - but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called ' skinny pens ' may also supercharge your brain and protect against two killer diseases. 3 3 Scientists from Taiwan found that these fat-busting jabs may help lower the chances of developing dementia and stroke. People with type 2 diabetes and obesity who took the drugs were also less likely to die early, the researchers discovered. While everyone knows these drugs, like Wegovy and Mounjaro, help with weight and blood sugar control, experts say some of their other benefits are still a bit of a mystery. For the study, published in JAMA Network Open, experts from Chang Gung Memorial Hospita l looked at data from 60,000 people around the world. The average age was 58 and all had type 2 diabetes and obesity. About half of the group were given drugs called GLP1-RAs. These include semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) to manage their diabetes. Semaglutide is also the main ingredient in the popular diabetes drug Ozempic, which is licensed for diabetes, while Wegovy is licensed for weight loss. These drugs work by lowering appetite, slowing digestion, reducing sugar production in the liver, and helping the body make more insulin when needed. The other half of the participants were on different diabetes medications. After following everyone for seven years, the researchers found the people using GLP1-RAs had a 37 percent lower risk of dementia and were 19 percent less likely to have a stroke. Weight Loss Jabs - Pros vs Cons These conditions are often called silent killers because they can creep up without obvious symptoms until it's too late. The experts also found those on the drugs were 30 per cent less likely to die during the study period. The team saw even bigger benefits in people over 60, women, and those with a body mass index between 30 and 40. There was no difference in the chances of Parkinson's disease or brain bleeds between the groups. The academics said their findings suggest "potential neuroprotective and cerebrovascular benefits" of the drugs but they called for more studies to confirm the research. "These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity," they wrote. Commenting on the study, Professor Tara Spires-Jones, from the University of Edinburgh, said: "This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. "This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. "It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. "Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity." 'This is a really exciting ' Dr Richard Oakley, from the Alzheimer's Society, said: "It is well established that diabetes and obesity can increase your risk of developing dementia. "This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. "Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. "There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia." Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines
